CLAIMS

1. A compound of the following Formula 1, or a pharmaceutically acceptable salt or isomer thereof:

[Formula 1]



wherein R1 is C_2-C_5 alkyl.

2. The compound, or a pharmaceutically acceptable salt or isomer thereof according to Claim 1, wherein R1 is C_2-C_4 alkyl.

3. The compound, or a pharmaceutically acceptable salt or isomer thereof according to Claim 2, wherein R1 is ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl.

4. The compound, or a pharmaceutically acceptable salt or isomer thereof according to Claim 2, wherein the compound is selected from the following group:

N-((3*S*,5*S*)-1-((3*S*,4*R*)-1-(*tert*-butyl)-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)-5-(morpholine-4-carbonyl)pyrrolidin-3-yl)-*N*-((1*s*,4*R*)-4-methylcyclohexyl)isobutyramide;

N-((3*S*,5*S*)-1-((3*S*,4*R*)-1-(*tert*-butyl)-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)-5-

morpholine-4-carbonyl)pyrrolidin-3-yl)-*N*-((1*s*,4*R*)-4-methylcyclohexyl)propionamide; and

N-((3*S*,5*S*)-1-((3*S*,4*R*)-1-(*tert*-butyl)-4-(4-chlorophenyl)pyrrolidine-3-carbonyl)-5-(morpholine-4-carbonyl)pyrrolidin-3-yl)-*N*-((1*s*,4*R*)-4-methylcyclohexyl)pivalamide.

5. The compound, or a pharmaceutically acceptable salt or isomer thereof according to Claim 1, wherein the pharmaceutically acceptable salt is selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid and hydroiodic acid.

6. The compound, or a pharmaceutically acceptable salt or isomer thereof according to Claim 5, wherein the pharmaceutically acceptable salt is hydrochloride.

7. A melanocortin receptor agonistic pharmaceutical composition comprising the compound of Formula 1, or a pharmaceutically acceptable salt or isomer thereof as defined in any one of Claims 1 to 6 as an active ingredient, together with a pharmaceutically acceptable carrier.

8. The melanocortin receptor agonistic pharmaceutical composition according to Claim 7, which is for use in the prevention or treatment of obesity.

9. The melanocortin receptor agonistic pharmaceutical composition according to Claim 7, which is for use in the prevention or treatment of diabetes.

10. The melanocortin receptor agonistic pharmaceutical composition according to Claim

7, which is for use in the prevention or treatment of inflammation.

11. The melanocortin receptor agonistic pharmaceutical composition according to Claim 7, which is for use in the prevention or treatment of erectile dysfunction.

12. Use of the melanocortin receptor agonistic pharmaceutical composition according to Claim 7 in the preparation of a medicament for the prevention or treatment of obesity.

13. Use of the melanocortin receptor agonistic pharmaceutical composition according to Claim 7 in the preparation of a medicament for the prevention or treatment of diabetes.

14. Use of the melanocortin receptor agonistic pharmaceutical composition according to Claim 7 in the preparation of a medicament for the prevention or treatment of inflammation.

15. Use of the melanocortin receptor agonistic pharmaceutical composition according to Claim 7 in the preparation of a medicament for the prevention or treatment of erectile dysfunction.

~~16. A method of preventing or treating obesity in a subject in need thereof, comprising administering the melanocortin receptor agonistic pharmaceutical composition according to Claim 7 to the subject.~~

~~17. A method of preventing or treating diabetes in a subject in need thereof, comprising administering the melanocortin receptor agonistic pharmaceutical composition~~

~~according to Claim 7 to the subject.~~

~~18. A method of preventing or treating inflammation in a subject in need thereof, comprising administering the melanocortin receptor agonistic pharmaceutical composition according to Claim 7 to the subject.~~

~~19. A method of preventing or treating erectile dysfunction in a subject in need thereof, comprising administering the melanocortin receptor agonistic pharmaceutical composition according to Claim 7 to the subject.~~